Apellis Pharmaceuticals Inc (NASDAQ: APLS) is -5.43% lower on its value in year-to-date trading and has touched a low of $19.83 and a high of $94.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APLS stock was last observed hovering at around $55.52 in the last trading session, with the day’s gains setting it 1.09%.
Currently trading at $56.61, the stock is -8.52% and -12.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing 1.96% at the moment leaves the stock 1.03% off its SMA200. APLS registered -8.84% loss for a year compared to 6-month gain of 16.65%. The firm has a 50-day simple moving average (SMA 50) of $16.60 and a 200-day simple moving average (SMA200) of -$13.30.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -15.37% loss in the last 1 month and extending the period to 3 months gives it a -2.36%, and is 0.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.68% over the week and 5.05% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 706 employees, a market worth around $6.83B and $396.59M in sales. Fwd P/E is 39.51. Profit margin for the company is -133.29%. Distance from 52-week low is 185.48% and -40.25% from its 52-week high. The company has generated returns on investments over the last 12 months (-176.79%).
Apellis Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.54 with sales reaching $161.78M over the same period.The EPS is expected to grow by 78.33% this year, but quarterly earnings will post 101.40% year-over-year. Quarterly sales are estimated to grow 260.70% in year-over-year returns.
405 institutions hold shares in Apellis Pharmaceuticals Inc (APLS), with institutional investors hold 110.59% of the company’s shares. The shares outstanding are 119.56M, and float is at 98.81M with Short Float at 10.19%. Institutions hold 95.96% of the Float.
The top institutional shareholder in the company is Avoro Capital Advisors LLC with over 11.11 million shares valued at $1.01 billion. The investor’s holdings represent 9.44% of the APLS Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 9.4 million shares valued at $856.46 million to account for 7.98% of the shares outstanding. The other top investors are Price (T.Rowe) Associates Inc which holds 7.07 million shares representing 6.01% and valued at over $644.28 million, while Wellington Management Group, LLP holds 5.66% of the shares totaling 6.66 million with a market value of $607.12 million.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
The most recent transaction is an insider sale by Dunlop A. Sinclair, the company’s Director. SEC filings show that Dunlop A. Sinclair sold 18,681 shares of the company’s common stock on Mar 19 ’24 at a price of $57.18 per share for a total of $1.07 million. Following the sale, the insider now owns 0.17 million shares.
Apellis Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 18 ’24 that DeLong Mark Jeffrey (Chief Business & Strat Officer) sold a total of 9,913 shares of the company’s common stock. The trade occurred on Mar 18 ’24 and was made at $56.90 per share for $0.56 million. Following the transaction, the insider now directly holds 54693.0 shares of the APLS stock.
Still, SEC filings show that on Mar 15 ’24, Chopas James George (VP/Chief Accounting Officer) disposed off 184 shares at an average price of $56.46 for $10389.0. The insider now directly holds 38,883 shares of Apellis Pharmaceuticals Inc (APLS).
